AI Summary
✦ ClarthaValuation Metrics
Trading 25.8% above historical median. Valuation is stable — currently in the strongly overvalued zone (z-score: +1.52). Confidence: 78%.
Live forward EPS implies next-12-month EPS of ₹28.58. Applying the stock's normalized valuation corridor produces a fair range of ₹606.75 to ₹912.56, with base value near ₹835.68 (-68.3% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹28.58
Forward P/E
92.4x
Base Fair Value
₹835.68
Fair Range
₹606.75 - ₹912.56
Upside To Base
-68.3%
Estimate Source
Live forward EPS
Growth Estimate
+17.0%
5Y Average
20.73
Current
36.79
Overvalued
31.93
Undervalued
21.23
5Y Average
15.03
Current
26.68
Overvalued
22.29
Undervalued
7.80
5Y Average
3.35
Current
5.95
Overvalued
4.97
Undervalued
1.74
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
CAPLIN POINT LAB LTD. CAPLIPOINTPharmaceuticals | +19.0% | 29.3% | 31.5x Undervalued | -53% vs avg | +22.8% |
ALIVUS LIFE SCIENCES LTD ALIVUSPharmaceuticals | +6.4% | 23.3% | 27.9x Undervalued | -58% vs avg | +43.2% |
CONCORD BIOTECH LIMITED CONCORDBIOPharmaceuticals | +26.2% | 24.8% | 49.0x Undervalued | -26% vs avg | -17.2% |
AKUMS DRUGS AND PHARMA L AKUMSPharmaceuticals | +9.6% | 5.9% | 44.4x Undervalued | -33% vs avg | +51.8% |
BLUE JET HEALTHCARE LTD BLUEJETPharmaceuticals | -17.4% | 26.5% | 43.8x Undervalued | -34% vs avg | -25.8% |
ASTRAZENECA PHARMA IND LT ASTRAZENPharmaceuticals | +20.4% | 8.2% | 107.8x Premium | +62% vs avg | -6.7% |
COHANCE LIFESCIENCES LTD COHANCEPharmaceuticals | -23.1% | 5.0% | 161.1x Premium | +142% vs avg | -52.5% |
RPG LIFE SCIENCES LTD trades at a discount (36.8x vs peer avg 66.5x), suggesting potential undervaluation relative to the Pharmaceuticals cohort. Peers include CAPLIN POINT LAB LTD., ALIVUS LIFE SCIENCES LTD, CONCORD BIOTECH LIMITED — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹177 CrMar 2026Latest net profit
₹29 CrMar 2026Latest EPS
₹18.08Mar 2026Net margin
15.3%Mar 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 118 | 148 | 154 | 154 | 127 | 165 | 172 | 173 | 143 | 169 | 182 | 180 | 177 |
| Expenses | 103 | 116 | 116 | 116 | 106 | 126 | 126 | 124 | 118 | 133 | 143 | 140 | 144 |
| Operating Profit | 12.02 | 28.03 | 33.06 | 33.76 | 16.23 | 33.78 | 40.62 | 43.7 | 20.12 | 30.33 | 33.81 | 34.38 | 27.13 |
| OPM % | 10.14% | 18.97% | 21.53% | 21.96% | 12.78% | 20.42% | 23.59% | 25.3% | 14.06% | 17.96% | 18.61% | 19.1% | 15.34% |
| Other Income | 1.84 | 1.81 | 1.83 | 1.92 | 1.65 | 2.37 | 1.94 | 3.31 | 5.06 | 5.23 | 4.54 | 3.41 | 12.36 |
| Interest | 0.05 | 0.07 | 0.1 | 0.14 | 0.14 | 0.15 | 0.17 | 0.12 | 0.18 | 0.13 | 0.12 | 0.25 | 0.39 |
| Depreciation | 3.89 | 4.21 | 4.23 | 4.14 | 4.49 | 5.29 | 5.31 | 5.46 | 5.37 | 5.14 | 5.22 | 5.38 | 5.74 |
| Profit before tax | 13.81 | 29.77 | 34.79 | 35.54 | 17.74 | 36 | 42.39 | 46.89 | 25 | 35.43 | 38.23 | 37.54 | 39.1 |
| Tax % | 25.05% | 25.76% | 25.67% | 25.55% | 25.37% | 25.67% | 25.69% | 25.51% | 70.2% | 25.8% | 32.96% | 18.62% | 26.34% |
| Net Profit | 10.35 | 22.1 | 25.86 | 26.46 | 13.24 | 26.76 | 31.5 | 34.93 | 7.45 | 26.29 | 25.63 | 30.55 | 28.8 |
| EPS in Rs | 6.26 | 13.36 | 15.64 | 16.00 | 8.01 | 16.18 | 2.54 | 21.12 | 70.96 | 15.90 | 22.28 | 13.38 | 18.08 |
All values in Rs. Crore unless otherwise stated. Source: CMIE Prowess, Quarterly Interim Standalone.